Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471061 | 0.86 | ALDH1A1 (0.36) | LMNAALDH1A1MAPTCCNT1CDK9 | |
| SCHEMBL15155089 | 0.86 | ALDH1A1 (0.37) | LMNAALDH1A1MAPTCCNT1CDK9 | |
| SCHEMBL1469043 | 0.78 | CCNT1 (0.44) | EGFRCCNT1CDK9CDK5CDK5R1 | |
| SCHEMBL15154894 | 0.76 | MAPT (0.39) | ALDH1A1MAPTHTT | |
| SCHEMBL15155185 | 0.76 | KDM4E (0.35) | LMNAALDH1A1MAPTRAB9AKDM4E | |
| SCHEMBL1468754 | 0.76 | MET (0.35) | LMNAALDH1A1MAPTRAB9ARECQL | |
| SCHEMBL1467726 | 0.73 | ALDH1A1 (0.33) | LMNAALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL1468836 | 0.73 | MAPT (0.35) | ALDH1A1MAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL25257796 | 0.71 | NPC1 (0.42) | LMNAEGFRALDH1A1MAPTNPC1 | |
| SCHEMBL1469636 | 0.71 | AAK1 (0.43) | MAPTRECQLKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969727-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160368916-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9365568-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2990407-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20150322061-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-11-12 | — | — | US | disclosed |
| CN-104926810-A | Pyrrolopyridines As Kinase Inhibitors | ARRAY BIOPHARMA INC | 2015-09-23 | — | — | CN | disclosed |
| EP-2307409-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-08-12 | — | — | EP | disclosed |
| CN-102089307-B | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC | 2015-07-01 | — | — | CN | disclosed |
| US-8981085-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140243520-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8758830-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140100369-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8545897-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130045286-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-8178131-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-05-15 | — | — | US | disclosed |
| CN-102089307-A | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC | 2011-06-08 | — | — | CN | disclosed |
| EP-2307409-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2009140320-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243520-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | LMNA 1596/4885EGFR 3452/4885ALDH1A1 2416/4885 |
| US-20160368916-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | LMNA 1596/4885EGFR 3452/4885ALDH1A1 2416/4885 |
| US-20140100369-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | LMNA 1596/4885EGFR 3452/4885ALDH1A1 2416/4885 |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | LMNA 1537/4885EGFR 2901/4885ALDH1A1 2477/4885 |
| US-20150322061-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | LMNA 1596/4885EGFR 3452/4885ALDH1A1 2416/4885 |
| US-20130045286-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | LMNA 1596/4885EGFR 3452/4885ALDH1A1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.